<DOC>
	<DOCNO>NCT01126190</DOCNO>
	<brief_summary>Determination effect Neugranin duration severity severe neutropenia subject receive doxorubicin combination docetaxel .</brief_summary>
	<brief_title>Neugranin Breast Cancer Patients Receiving Doxorubicin/Docetaxel ( NEUGR-003 )</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Breast cancer patient schedule receive AT regimen ( doxorubicin/ docetaxel ) Subjects may receive 1 prior chemotherapy regimen ( include adjuvant therapy give within last 12 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>